Structural and Functional Neuroimaging Studies of Combat Veterans
| Status: | Completed |
|---|---|
| Conditions: | Neurology, Psychiatric |
| Therapuetic Areas: | Neurology, Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/5/2019 |
| Start Date: | January 26, 2011 |
| End Date: | February 3, 2014 |
Background:
- Studies have shown that some people develop post-traumatic stress disorder (PTSD) after
being exposed to the trauma of military combat. They may have repeated thoughts, images, and
dreams of the trauma; feel detached from others; have difficulty sleeping and concentrating;
or be easily startled. Some studies have also shown that after having a blow or blast to the
head, some people may develop post-concussive syndrome (PCS), which may include symptoms such
as headaches, difficulty concentrating, and feeling moody or irritable. Researchers are
interested in using magnetic resonance imaging (MRI) to study combat veterans from Operation
Iraqi Freedom or Operation Enduring Freedom in order to evaluate possible changes in the
brain that may be attributed to PTSD or PCS.
Objectives:
- To evaluate changes in brain function in recent combat veterans that may be related to
post-traumatic stress disorder or post-concussive syndrome.
Eligibility:
- Combat veterans of Operation Iraqi Freedom/Operation Enduring Freedom who are enrolled in
Walter Reed Army Medical Center protocol 351030, have returned within the last 6 weeks from a
deployment in Iraq or Afghanistan that lasted at least 3 months, and are able to have
magnetic resonance imaging scans.
Design:
- This study involves between 1 and 4 outpatient visits to the NIH Clinical Center over
the course of 1 year. The second, third, and fourth visits will occur 3, 6, and 12
months after the first visit.
- At the first visit, participants will have a baseline MRI scan, followed by a functional
MRI (fMRI) scan to see what parts of the brain are used while performing simple tasks
and responding to images. Participants will complete questionnaires after the scan to
report on their experiences during the MRI scan.
- For the remaining three study visits, participants will have further MRI and fMRI scans
and will complete additional questionnaires. Participation is complete after the
12-month study visit, or following a diagnosis of PTSD, major depression, or PCS at any
time during the study.
- No treatment will be provided as part of this protocol.
- Studies have shown that some people develop post-traumatic stress disorder (PTSD) after
being exposed to the trauma of military combat. They may have repeated thoughts, images, and
dreams of the trauma; feel detached from others; have difficulty sleeping and concentrating;
or be easily startled. Some studies have also shown that after having a blow or blast to the
head, some people may develop post-concussive syndrome (PCS), which may include symptoms such
as headaches, difficulty concentrating, and feeling moody or irritable. Researchers are
interested in using magnetic resonance imaging (MRI) to study combat veterans from Operation
Iraqi Freedom or Operation Enduring Freedom in order to evaluate possible changes in the
brain that may be attributed to PTSD or PCS.
Objectives:
- To evaluate changes in brain function in recent combat veterans that may be related to
post-traumatic stress disorder or post-concussive syndrome.
Eligibility:
- Combat veterans of Operation Iraqi Freedom/Operation Enduring Freedom who are enrolled in
Walter Reed Army Medical Center protocol 351030, have returned within the last 6 weeks from a
deployment in Iraq or Afghanistan that lasted at least 3 months, and are able to have
magnetic resonance imaging scans.
Design:
- This study involves between 1 and 4 outpatient visits to the NIH Clinical Center over
the course of 1 year. The second, third, and fourth visits will occur 3, 6, and 12
months after the first visit.
- At the first visit, participants will have a baseline MRI scan, followed by a functional
MRI (fMRI) scan to see what parts of the brain are used while performing simple tasks
and responding to images. Participants will complete questionnaires after the scan to
report on their experiences during the MRI scan.
- For the remaining three study visits, participants will have further MRI and fMRI scans
and will complete additional questionnaires. Participation is complete after the
12-month study visit, or following a diagnosis of PTSD, major depression, or PCS at any
time during the study.
- No treatment will be provided as part of this protocol.
Objective: Traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD) are linked
with functional impairments, poor outcomes compared to matched controls or people without
brain dysfunction, and greater healthcare utilization. TBI can be diagnosed at the point of
injury, but post-concussive syndrome (PCS) and PTSD are diagnosed after the initial exposure.
Current treatments are often ineffective, and many affected military service members (SMs)
never return to active duty. Upon return from deployment, many SMs experience an initial
honeymoon period during which symptoms are limited in number and scope, but this may be
followed by a sharp increase in symptoms within months. Identification of independent
predictors of PTSD and PCS upon return from deployment could facilitate early intervention to
prevent disability. The main purpose of this protocol is to determine whether structural and
functional neuroimaging in SMs who are ostensibly healthy upon return can differentiate those
who will go on to have persistent neurocognitive difficulties from those who will not.
Study population: The study population will be returning SMs at risk for PCS or PTSD. It
involves a prospective cohort study of 128 healthy active duty military SMs, recruited by the
Walter Reed National Military Medical Center (WRNMMC) from National Capital Area military
units within 8 weeks after return from Iraq or Afghanistan, with serial evaluations to
identify both those who develop PTSD or PCS, as well as factors obtained at the time of the
initial evaluation that prove to be most strongly associated with subsequent PTSD and PCS. A
comprehensive baseline assessment will be performed at WRNMMC under protocol 351030 (already
approved at both the Uniformed Services University of Health Sciences [USUHS] and WRNMMC),
which will include demographics, neuropsychological assessment, genetic and neuroendocrine
assays, brain imaging and synchronization, vestibular, olfactory, and psychophysiologic
measures. Neuroimaging and fMRI activation tasks will be performed under this imaging
protocol at NIH. The study is funded by the USUHS Center for Neuroscience and Regenerative
Medicine (CNRM) and NIH. See the attached WRNMMC protocol 351030.
Design: Neuroimaging including structural and functional magnetic resonance imaging (fMRI),
and diffusion tension imaging (DTI) will be performed under this imaging protocol at NIH.
Follow-up visits at 3, 6, and 12 months will allow repeated MRIs and fMRI activation tasks.
Data analysis will include serial univariate and multivariate analyses to identify the
baseline measures (including not only the results from this imaging study at NIH but also the
results from a variety of studies to be performed at WRNMMC) that are most strongly
associated with the subsequent development of PTSD and PCS.
Outcome measures: The primary outcome of interest is the development of neurocognitive
difficulties (PCS, PTSD, or depression). Multivariate analyses will assess what baseline
measures are most strongly associated with this outcome.
with functional impairments, poor outcomes compared to matched controls or people without
brain dysfunction, and greater healthcare utilization. TBI can be diagnosed at the point of
injury, but post-concussive syndrome (PCS) and PTSD are diagnosed after the initial exposure.
Current treatments are often ineffective, and many affected military service members (SMs)
never return to active duty. Upon return from deployment, many SMs experience an initial
honeymoon period during which symptoms are limited in number and scope, but this may be
followed by a sharp increase in symptoms within months. Identification of independent
predictors of PTSD and PCS upon return from deployment could facilitate early intervention to
prevent disability. The main purpose of this protocol is to determine whether structural and
functional neuroimaging in SMs who are ostensibly healthy upon return can differentiate those
who will go on to have persistent neurocognitive difficulties from those who will not.
Study population: The study population will be returning SMs at risk for PCS or PTSD. It
involves a prospective cohort study of 128 healthy active duty military SMs, recruited by the
Walter Reed National Military Medical Center (WRNMMC) from National Capital Area military
units within 8 weeks after return from Iraq or Afghanistan, with serial evaluations to
identify both those who develop PTSD or PCS, as well as factors obtained at the time of the
initial evaluation that prove to be most strongly associated with subsequent PTSD and PCS. A
comprehensive baseline assessment will be performed at WRNMMC under protocol 351030 (already
approved at both the Uniformed Services University of Health Sciences [USUHS] and WRNMMC),
which will include demographics, neuropsychological assessment, genetic and neuroendocrine
assays, brain imaging and synchronization, vestibular, olfactory, and psychophysiologic
measures. Neuroimaging and fMRI activation tasks will be performed under this imaging
protocol at NIH. The study is funded by the USUHS Center for Neuroscience and Regenerative
Medicine (CNRM) and NIH. See the attached WRNMMC protocol 351030.
Design: Neuroimaging including structural and functional magnetic resonance imaging (fMRI),
and diffusion tension imaging (DTI) will be performed under this imaging protocol at NIH.
Follow-up visits at 3, 6, and 12 months will allow repeated MRIs and fMRI activation tasks.
Data analysis will include serial univariate and multivariate analyses to identify the
baseline measures (including not only the results from this imaging study at NIH but also the
results from a variety of studies to be performed at WRNMMC) that are most strongly
associated with the subsequent development of PTSD and PCS.
Outcome measures: The primary outcome of interest is the development of neurocognitive
difficulties (PCS, PTSD, or depression). Multivariate analyses will assess what baseline
measures are most strongly associated with this outcome.
- INCLUSION CRITERIA:
Warfighters who:
1. Are enrolled in WRNMMC protocol 351030.
2. Have returned within the previous 8 weeks from a deployment of at least 3 months
duration in Iraq or Afghanistan.
EXCLUSION CRITERIA:
Warfighters who:
1. Are not able to hear normal conversation.
2. Do not have visual acuity correctable to 20/100 in at least one eye.
3. Have had a head injury resulting in loss of consciousness for 60 minutes or more or
have a current Glasgow Coma Scale < 14.
4. Meet criteria for PTSD, major depression, or post-concussive syndrome at the time of
the initial evaluation at WRNMMC. (A history of one or more of these conditions in the
past is not exclusionary as long as criteria are not met at the time of evaluation).
5. Have active psychotic symptoms, or active suicidal or homicidal ideation, identified
on the medical history, Patient Health Questionnaire, or Clinician-Administered PTSD
Scale.
6. Are pregnant as shown by a pregnancy test taken during the baseline intake at WRNMMC.
7. Have retained metal fragments (shrapnel), body piercings that cannot be removed, or
other imbedded ferromagnetic metal resulting from trauma or surgery, which would pose
a risk for MRI scanning.
8. Have significant claustrophobia, including but not limited to intolerance of magnetic
resonance imaging in the past, as we cannot provide sedating medications with the
scans due to the potential impact of the medications on interpretation of scan
results.
9. Report that they regularly drink 3 or more alcoholic beverages a day.
10. Report that they take illegal drugs.
11. Report that they are unable to abstain from the use of alcohol, narcotics,
benzodiazepines, or sleep medication for 24 hours before being scanned.
12. Are on calcium channel blockers (e.g., verapamil, nifedipine) or alpha-blockers (e.g.,
prazosin, terazosin) and are unable to stop these medications for a 24-hour period
prior to scanning. They will be excluded due to the impact of these medications on the
interpretation of fMRI imaging.
13. Are ill with active Acinetobacter or other clinically significant infection as
identified during their military evaluation upon their return from theater.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Click here to add this to my saved trials
